#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Osteoprotegerin and its Ligand


Authors: Stejskal D.';  Pastorková R.';  Růžička V.';  Oral L';  J. Bartek 2;  Horalík D.'
Authors‘ workplace: IOddělení laboratorní medicíny a interní oddělení Nemocnice Šternberk primář MUDr. D. Stejskal 2Ústav lékařské chemie a biochemie LF UP, Olomouc, přednosta MUDr. J. Bartek
Published in: Prakt. Lék. 2002; (4): 191-193
Category:

Overview

Osteoprotegerin and its ligand (so-called RANKL) are substances which influence in an important way bone resorption (OPG inhibits osteoclastogenesis and its ligand stimulates it). Both substances are produced by the osteoblastic cell line, they are found in the blond stream in the free form and they can thus be estimated. The effects of OPG/RANKL are intensely studied in retem years. On animal models evidence was provided tkat OPG deficient mice have osteoporosis and vice ýersa. Also according to the results of the majority of clinical studies it seems tkat there exists an invers relationship between OPG and bone density. There are attempts to apply the OPG/RANKL method in research of malignant primary and secondary osseous fotí, myelomas, vascular calcifications etc. Therapeutic administration of osteoprotegerin in experiments proved useful in individuals with severe osteoporosis, destructive skeletal disease, in metastatizing carcinomas of the mammary gland, large intestine and prostaty, osteosarcoma or after ovariectomy. In thus treated subjects also a significant reduction of experimentally induced calcifications occurred.

Key words:
osteprotegerin - RANKL - RANK - osteoporosis - osteopetrosis - myeloma -

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#